ELUT today
$0.92-$0.01 (-1.38%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourExpanding
15 minBearish
5 minConsolidating
Daily trend turns up above $1.05
Key levels
Resistance$1.17
Resistance$1.05
Support$0.88
Support$0.80
Latest news & SEC filings
EarningsElutia Releases Q3 2026 Results Alongside Business Update
EarningsElutia Discusses Third-Quarter 2026 Results on Conference Call
ProductElutia sets Q4 2026 FDA filing for NXT-41x, NXT-41 ruling due this quarter
All ELUT news →About Elutia
Elutia makes drug-eluting biomatrix products for surgical reconstruction and soft tissue repair. Its marketed offerings include a dermal graft for plastic and reconstructive procedures plus cardiovascular patches used in heart tissue repair. The company is developing next-generation biologic scaffolds that release antibiotics locally at the surgical site. Products are sold to healthcare facilities across the United States through independent sales agents.
Based on the company's 10-K filed Mar 13, 2026.
Nasdaq · Healthcare
ELUTIA INC. (ELUT)
What Is the Price Target for ELUT?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ELUT a Buy or Sell Right Now?
Thesis
- •Revenue growing -15.0% YoY with DECLINING trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ELUT.
Start Free Trial →Is ELUT Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG
Fair Value
$-0.08
41
Moat Score
NARROW
5/9
Piotroski Score
-4.0
Altman Z-Score
What Is Smart Money Doing with ELUT?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Williams Michelle LeRoux | officer | Buy | 12,500 | - | Sep 10, 2026 |
| Williams Michelle LeRoux | officer | Sale | 4,269 | $3K | Sep 10, 2026 |
| Ferguson Matthew | officer | Buy | 12,500 | - | Sep 10, 2026 |
| Ferguson Matthew | officer | Sale | 4,486 | $4K | Sep 10, 2026 |
| Mills C Randal | director officer | Buy | 27,083 | - | Sep 10, 2026 |
| Mills C Randal | director officer | Sale | 9,718 | $8K | Sep 10, 2026 |
| Williams Michelle LeRoux | officer | Sale | 4,269 | $4K | Jun 10, 2026 |
| Mills C Randal | director officer | Sale | 9,718 | $10K | Jun 10, 2026 |
| Ferguson Matthew | officer | Sale | 4,485 | $5K | Jun 10, 2026 |
| RAKIN KEVIN | director 10% owner | Sale | 70,000 | - | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ELUT Growth Story
Revenue YoY
-15.0%
3yr Revenue CAGR
-19.8%
EPS Growth YoY
146.77%
FCF Growth YoY
-100.3%
Revenue Trend
DECLINING
Dark Pool Trades for ELUT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ELUT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:10:46 | $0.90 | 1,813 | $$2K | SELL |
| 17:03:23 | $0.92 | 3,430 | $$3K | SELL |
| 16:27:29 | $0.92 | 2,500 | $$2K | SELL |
| 16:26:32 | $0.92 | 1,000 | $$920 | SELL |
| 16:26:24 | $0.94 | 1,000 | $$935 | SELL |
5 dark pool trades shown · $$9K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ELUTIA INC. (ELUT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ELUT — frequently asked questions
What is ELUT stock price today?
ELUTIA INC. (ELUT) is at $0.92, down 1.38% (-$0.01) at the Nov 11, 2026 close.
Why is ELUT stock moving today?
Latest ELUT news — Nov 7, 2026: Elutia Releases Q3 2026 Results Alongside Business Update · Nov 5, 2026: Elutia Discusses Third-Quarter 2026 Results on Conference Call
Did ELUT beat earnings?
ELUT last reported on Aug 13, 2026: EPS -$0.17 vs -$0.15 expected — a miss of 13.3%.
What is ELUT's P/E ratio?
ELUT trades at a P/E of 0.8 vs a Healthcare average of 17.9.
Does ELUT pay a dividend?
ELUT does not currently pay a dividend.
What are ELUT support and resistance levels?
Support: $0.88, $0.80, $0.70. Resistance: $1.05, $1.17, $1.28.
What are insiders doing with ELUT?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on ELUT?
Nov 7, 2026: Elutia Releases Q3 2026 Results Alongside Business Update · Nov 5, 2026: Elutia Discusses Third-Quarter 2026 Results on Conference Call · Nov 5, 2026: Elutia sets Q4 2026 FDA filing for NXT-41x, NXT-41 ruling due this quarter